Related Experiment Video
Updated: Aug 23, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1
Shiqiang Dong1, Dingkun Hou1, Yun Peng2
1Department of Oncology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Abstract:
Microtubule-interacting and trafficking domain containing 1 (MITD1) is associated with abscission during cytokinesis. However, systematic investigation into its role in cancer is lacking. Therefore, we explored the pan-cancer role of MITD1 using multiple databases. Expression and clinical survival, immunological, and enrichment analyses were performed using R packages and online tools. For breast cancer, single-cell level analysis, immunochemistry, and in vitro experiments were performed to explore the mechanism of MITD1. A nomogram was established to predict the prognosis of patients with breast cancer and evaluate the immunotherapy biomarker based on two datasets. In some cancers, high MITD1 expression was associated with a more favorable prognosis. For instance, it inhibited tumor cell proliferation and migration in breast cancer. MITD1 may regulate cancer development by altering the tumor microenvironment, and MITD1 expression may predict the response to immune checkpoint blockade, platinum, and poly ADP-ribose polymerase inhibitor therapies. Our nomogram was used to determine the prognosis of patients with breast cancer. MITD1 can also predict the response to immunotherapy. Our first pan-cancer study of MITD1 has shown that it plays different roles in cancer development and therapy. In breast cancer, MITD1 inhibited cell proliferation and migration and serves as a new biomarker.
Insights
Microtubule-interacting and trafficking domain containing 1 (MITD1) plays varied roles in cancer, inhibiting proliferation and migration in breast cancer. High MITD1 expression may predict better prognosis and response to certain therapies, serving as a potential biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Microtubule-interacting and trafficking domain containing 1 (MITD1) is linked to cell division but its cancer relevance is understudied.
- Systematic investigation into MITD1's pan-cancer role and therapeutic implications is lacking.
Purpose of the Study:
- To explore the comprehensive role of MITD1 across various cancers.
- To investigate MITD1's prognostic and predictive value, particularly in breast cancer.
- To establish a predictive model for breast cancer patient prognosis and immunotherapy response.
Main Methods:
- Pan-cancer analysis of MITD1 expression, clinical survival, and immunological data using R and online tools.
- In-depth analysis for breast cancer including single-cell, immunohistochemistry, and in vitro experiments.
- Development of a nomogram for prognosis prediction and immunotherapy biomarker evaluation.
Main Results:
- MITD1 expression showed varied associations with prognosis across different cancers; high MITD1 correlated with favorable outcomes in some.
- In breast cancer, MITD1 inhibited tumor cell proliferation and migration.
- MITD1 expression may predict patient response to immune checkpoint blockade, platinum, and PARP inhibitor therapies.
Conclusions:
- MITD1 exhibits diverse functions in cancer development and treatment across different tumor types.
- MITD1 acts as a tumor suppressor in breast cancer, inhibiting proliferation and migration.
- MITD1 is a potential prognostic biomarker and predictor of therapeutic response in cancer, especially breast cancer.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018